Navigation Links
Clay key to high-temperature supercapacitors
Date:9/3/2013

HOUSTON (Sept. 3, 2013) Clay, an abundant and cheap natural material, is a key ingredient in a supercapacitor that can operate at very high temperatures, according to Rice University researchers who have developed such a device.

The Rice group of materials scientist Pulickel Ajayan reported today in Nature's online journal, Scientific Reports that the supercapacitor is reliable at temperatures of up to 200 degrees Celsius (392 degrees Fahrenheit) and possibly beyond. It could be useful for powering devices for use in extreme environments, such as oil drilling, the military and space.

"Our intention is to completely move away from conventional liquid or gel-type electrolytes, which have been limited to low-temperature operation of electrochemical devices," said Arava Leela Mohana Reddy, lead author and a former research scientist at Rice.

"We found that a clay-based membrane electrolyte is a game-changing breakthrough that overcomes one of the key limitations of high-temperature operation of electrochemical energy devices," Reddy said. "By allowing safe operation over a wide range of temperatures without compromising on high energy, power and cycle life, we believe we can dramatically enhance or even eliminate the need for expensive thermal management systems."

A supercapacitor combines the best qualities of capacitors that charge in seconds and discharge energy in a burst and rechargeable batteries that charge slowly but release energy on demand over time. The ideal supercapacitor would charge quickly, store energy and release it as needed.

"Researchers have been trying for years to make energy storage devices like batteries and supercapacitors that work reliably in high-temperature environments, but this has been challenging, given the traditional materials used to build these devices," Ajayan said.

In particular, researchers have struggled to find an electrolyte, which conducts ions between a ba
'/>"/>

Contact: Mike Williams
mikewilliams@rice.edu
713-348-6728
Rice University
Source:Eurekalert

Page: 1 2 3

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
(Date:7/11/2014)... from Ume University, Sweden, have explored two different ... reaction sequence leading to the formation of oxygen ... published in the scientific journal Nature Communications ... present day synthetic catalysts for water oxidation, which ... for the direct storage of solar energy in ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
... 25, 2012  ChromaDex Corporation (OTCBB: CDXC), an innovative ... and ingredients to the dietary supplement, food & ... its BluScience ( www.bluscience.com ) line ... McKesson to approximately 4,000 independent drugstores and pharmacies. ...
... five leading causes of death. And yet, despite ... treatment for most cancers. In addition, disappointing results ... the need for alternative methods. Mathematical ... of tumors in terms of differential equations and ...
... Research!America,s Board chair, former Congressman John Edward Porter (R-IL), ... in basic research. , "America,s leadership is at ... in discovery and development," said Porter. "We could ... Europe integrate science and technology into economic growth while ...
Cached Biology News:ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 2ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 3ChromaDex® Expands National Launch of its BluScience™ Line of Dietary Supplements Through McKesson 4Aiding cancer therapy by mathematically modeling tumor-immune interactions 2Aiding cancer therapy by mathematically modeling tumor-immune interactions 3State of the Union speech: Promising outlook for research and innovation 2
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced financial ... The net income for the first quarter ended March ... of $14.1 million during the same period in 2010. Net ... related primarily to the $34.2 million in collaboration revenue recognized ...
... 2011 Silence Therapeutics plc (AIM: ... of patent 4,705,370, titled "Further Novel Forms of ...  The issued patent covers aspects of Silence,s platform ... 2,-O-Methyl structures known as AtuRNAi.  Silence,s AtuRNAi molecules ...
... May 2, 2011 Dendreon Corporation (Nasdaq: DNDN ) ... Revenue for the quarter ended March 31, 2011 was $28.1 million ... The GAAP net loss for the quarter ended March ... $125.7 million, or $0.96 per share for the quarter ended March ...
Cached Biology Technology:MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology 2Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology 3Dendreon Reports First Quarter 2011 Financial Results 2Dendreon Reports First Quarter 2011 Financial Results 3Dendreon Reports First Quarter 2011 Financial Results 4Dendreon Reports First Quarter 2011 Financial Results 5
Request Info...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: